Myriad Genetics (MYGN) closed at $6.02 on November 4, 2026, down 0.3% from the previous close, on volume of 1,854,163 shares (30-day average 2,586,698).
Data as of November 4, 2026.
Myriad unauthorized IT access prompted temporary testing, order suspension
Seeking Alpha News (Thu, 5-Nov 11:04 AM ET)
Myriad Genetics Reports Cybersecurity Incident, Investigates Potential Data Access
TipRanks (Thu, 5-Nov 9:31 AM ET)
Myriad Genetics (MYGN) Receives a Hold from Leerink Partners
TipRanks (Thu, 5-Nov 9:29 AM ET)
Myriad Genetics (MYGN) was upgraded to a Hold Rating at Piper Sandler
TipRanks (Thu, 5-Nov 7:27 AM ET)
Myriad Genetics Non-GAAP EPS of -$0.11 beats by $0.09, revenue of $202.7M beats by $11.37M
Seeking Alpha News (Wed, 4-Nov 4:23 PM ET)
Globe Newswire (Wed, 4-Nov 4:05 PM ET)
Here are the major earnings after the close Wednesday
Seeking Alpha News (Wed, 4-Nov 10:00 AM ET)
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
Globe Newswire (Mon, 2-Nov 4:05 PM ET)
Globe Newswire (Thu, 22-Oct 9:05 AM ET)
Market Chameleon (Tue, 20-Oct 5:52 AM ET)
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
Myriad Genetics trades on the NASDAQ stock market under the symbol MYGN.
As of November 5, 2026, MYGN stock price climbed to $6.22 with 2,102,373 million shares trading.
MYGN has a beta of -0.18, meaning it tends to be less sensitive to market movements. MYGN has a correlation of 0.00 to the broad based SPY ETF.
MYGN has a market cap of $587.44 million. This is considered a Small Cap stock.
Last quarter Myriad Genetics reported $203 million in Revenue and -$.11 earnings per share. This beat revenue expectation by $12 million and exceeded earnings estimates by $.10.
In the last 3 years, MYGN traded as high as $29.30 and as low as $2.74.
The top ETF exchange traded funds that MYGN belongs to (by Net Assets): XBI, IWM, VTI, IWN, VXF.
MYGN has underperformed the market in the last year with a return of -3.7%, while SPY returned +10.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in MYGN shares. However, MYGN has outperformed the market in the last 3 month and 2 week periods, returning +96.2% and +11.7%, while SPY returned -4.2% and -4.6%, respectively. This indicates MYGN has been having a stronger performance recently.
MYGN support price is $5.71 and resistance is $6.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MYGN shares will trade within this expected range on the day.
